Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 3:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 442 matching trials from the live ClinicalTrials.gov search.
Filters: "motor neuron disease" Condition: ALS Clear all
Completed No phase listed Observational Accepts healthy volunteers

Exploring Accessible Beauty for Individuals With Upper Extremity Deficits

NCT05945784
View directory record Official record
Conditions
Stroke, Ischemic, Stroke Hemorrhagic, Stroke (CVA) or TIA, Stroke, Acute, Traumatic Brain Injury, SCI - Spinal Cord Injury, Ehlers-Danlos Syndromes (EDS), Lupus Erythematosus, Guillain-Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Amyotrophic Lateral Sclerosis, Graves Disease, Muscular Dystrophies
Interventions
Use of Rare Beauty makeup products
Other
Lead sponsor
Casa Colina Hospital and Centers for Healthcare
Other
Eligibility
18 Years to 55 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 14, 2026, 3:49 PM EDT
Completed Phase 1 Interventional

A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis

NCT05006352
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
DNL343, Placebo
Drug
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Scottsdale, Arizona • San Diego, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 14, 2026, 3:49 PM EDT
Completed Phase 2Phase 3 Interventional

Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement

NCT00386464
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
noninvasive positive pressure ventilation
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2007 · Synced Oct 14, 2026, 3:49 PM EDT
Completed Phase 2 Interventional Results available

Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)

NCT00931944
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
KNS-760704
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
21 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
19
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 14, 2026, 3:49 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

NCT05053035
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AL001, Placebo
Drug
Lead sponsor
Alector Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Tampa, Florida • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 14, 2026, 3:49 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

NuroSleeve Powered Brace & Stimulation System to Restore Arm Function

NCT04798378
View directory record Official record
Conditions
Neurologic Diseases, Hemiparesis, Quadriplegia, Muscular Dystrophies, Arthrogryposis, Spinal Cord Injuries, Charcot-Marie-Tooth, Stroke, Weakness of Extremities as Sequela of Stroke, Weakness Due to Upper Motor Neuron Dysfunction, Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy, Arm Paralysis, Cerebral Palsy
Interventions
Neurosleeve
Device
Lead sponsor
Thomas Jefferson University
Other
Eligibility
4 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
2
States / cities
Wilmington, Delaware • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 14, 2026, 3:49 PM EDT
Recruiting Not applicable Interventional

Tongue-strengthening Exercises in People With ALS.

NCT07295990
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis
Interventions
Isometric Lingual Strength Exercises
Procedure
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Davie, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 14, 2026, 3:49 PM EDT
Completed Phase 2 Interventional

A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT01089010
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo, 250 mg CK-2017357, 500 mg CK-2017357
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
15
States / cities
Phoenix, Arizona • Fresno, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 14, 2026, 3:49 PM EDT
Recruiting Phase 2 Interventional

A Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS)

NCT07071935
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Chronic Respiratory Failure, Neuromuscular Disease Patients, Neuromuscular Disease, Respiratory Insufficiency, Respiratory Insufficiency Requiring Mechanical Ventilation, Positive Pressure Ventilation, Non-invasive Ventilation, Non-invasive Ventilation Support, Non-invasive Ventilatory Support
Interventions
Non-invasive ventilation
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania • Philadelphi, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 14, 2026, 3:49 PM EDT
Completed Phase 2 Interventional

A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS)

NCT00230074
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
TCH346
Drug
Lead sponsor
Novartis
Industry
Eligibility
21 Years to 80 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Oct 14, 2026, 3:49 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation

NCT04494256
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIIB105, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
14
States / cities
Phoenix, Arizona • La Jolla, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 14, 2026, 3:49 PM EDT
Completed Phase 2 Interventional

Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis

NCT00005766
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Creatinine
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 3:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Remote Ischemic Conditioning on Hand Use in Individuals With SCI and ALS

NCT03851302
View directory record Official record
Conditions
Spinal Cord Injuries, Amyotrophic Lateral Sclerosis
Interventions
Active Remote Ischemic Conditioning, Sham Remote Ischemic Conditioning, Isometric hand exercise
Other
Lead sponsor
Bronx VA Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 14, 2026, 3:49 PM EDT
Completed Phase 1 Interventional

A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis

NCT01609283
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
autologous mesenchymal stem cells
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Oct 14, 2026, 3:49 PM EDT
Recruiting Phase 2 Interventional

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

NCT07142291
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Placebo, Riluzole (100 mg)
Drug
Lead sponsor
PhenoNet, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • La Jolla, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 14, 2026, 3:49 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

NCT06100276
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AMT-162
Drug
Lead sponsor
UniQure Biopharma B.V.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
11
States / cities
Phoenix, Arizona • Irvine, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 14, 2026, 3:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants

NCT05795907
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (Healthy Volunteers)
Interventions
SAR443820, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 14, 2026, 3:49 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT04499963
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Theracurmin HP
Drug
Lead sponsor
Richard Bedlack, M.D., Ph.D.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 14, 2026, 3:49 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

NCT04057898
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
MN-166, placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 80 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
10
States / cities
Orange, California • Jacksonville, Florida • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 14, 2026, 3:49 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS

NCT07169175
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
SNUG01
Drug
Lead sponsor
SineuGene Therapeutics Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 14, 2026, 3:49 PM EDT
Completed Not applicable Interventional Results available

Study of Standard Noninvasive Positive Pressure Ventilation (NIPPV) and Low Expiratory Pressure NIPPV in ALS Patients

NCT01154283
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Viasys® Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)
Device
Lead sponsor
Kirsten Gruis
Other
Eligibility
19 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 14, 2026, 3:49 PM EDT
Completed Not applicable Interventional Results available

Effectiveness of Expiratory Muscle Strength Training for Improving Communication in ALS

NCT05003167
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Expiratory Muscle Strength Training (EMST-150)
Device
Lead sponsor
Purdue University
Other
Eligibility
40 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 14, 2026, 3:49 PM EDT
Completed Not applicable Interventional Results available

Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation

NCT00116558
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Early NIPPV, Standard NIPPV
Device
Lead sponsor
Edward Kasaraskis
Other
Eligibility
18 Years to 80 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
12
States / cities
Denver, Colorado • Miami, Florida • Lexington, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 14, 2026, 3:49 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Novel MRI Biomarkers for Monitoring Disease Progression in ALS

NCT03362658
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions
Not listed
Lead sponsor
University of Alberta
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
2
States / cities
Miami, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 14, 2026, 3:49 PM EDT